There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology…

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate - European Business & Finance Magazine

SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage,